Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
117 hedge funds and large institutions have $241M invested in Infinity Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 17 closing their positions.
62% more call options, than puts
Call options by funds: $1.38M | Put options by funds: $850K
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
2% more funds holding
Funds holding: 115 → 117 (+2)
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
91% less capital invested
Capital invested by funds: $2.76B → $241M (-$2.52B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.11M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.81M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.9M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.82M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$2.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Americafirst Capital Management
Roseville,
California
|
-$2.38B |
| 2 |
Goldman Sachs
New York
|
-$7.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.48M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$6.64M |
| 5 |
O
OrbiMed
New York
|
-$4.24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Jane Street
New York
| – | -$118K | -15,073 | Closed |
|
|
DIA
127
Denver Investment Advisors
Denver,
Colorado
| – | -$102K | -12,939 | Closed |
|
128
BNP Paribas Financial Markets
Paris,
France
| – | -$88K | -11,212 | Closed |
|
|
AIM
129
Alambic Investment Management
Belvedere,
California
| – | -$83K | -10,597 | Closed |
|
|
TDC
130
Thompson Davis & Co
Richmond,
Virginia
| – | -$39K | -5,000 | Closed |
|
|
RFC
131
Russell Frank Company
Seattle,
Washington
| – | -$37K | -4,700 | Closed |
|
|
CG
132
Cutler Group
San Francisco,
California
| – | -$11.1K | -1,806 | Closed |
|
|
BJ
133
BlackRock Japan
Tokyo,
Japan
| – | -$3K | -352 | Closed |
|
|
GT
134
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$1.13K | +185 | New |
|
INFI Hedge Fund Activity: Q1 2016 in Review
117 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2016, worth a combined $241M — down 91% from $2.76B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new INFI positions and 17 closed out — a net gain of 5 holders — while 36 added to existing stakes and 35 trimmed.
The largest buyer was Ameriprise, adding an estimated $6.11M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $2.38B sold.
- 117 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2016, up from 115 in Q4 2015.
- Funds reported $241M of Infinity Pharmaceuticals, Inc. stock for Q1 2016, down 91% quarter-over-quarter.
- 22 funds opened new Infinity Pharmaceuticals, Inc. positions in Q1 2016 and 17 closed out, a net change of +5 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q1 2016 was Ameriprise, an estimated $6.11M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2016 was Americafirst Capital Management, an estimated $2.38B sold.
Based on aggregated 13F filings for Q1 2016.